1 Incubation of the class I antiarrhythmic drug aprindine (AP) with human liver microsomes resulted in the formation of two hydroxylated metabolites (HA1 and HA2) and desethylaprindine which were identified by GC-mass spectrometry. In liver microsomes isolated from a poor metaboliser (PM) of sparteine no hydroxylated metabolites of AP were detected whereas AP N-dealkylation was unimpaired. Thus hydroxylation of AP is mediated by cytochrome P450 2D6 (CYP2D6). 2 AP was found to be a competitive inhibitor of CYP2D6 as indicated by its ability to impair the formation of (2S)-hydroxysparteine, 5,6-didehydrosparteine and 5-hydroxypropafenone by human liver microsomes. 3 These in vitro findings are consistent with a major role of CYP2D6 in the clearance of AP in vivo, with its ability to impair the metabolism of other CYP2D6 substrates in vivo, and an ability to cause phenocopying (conversion of extensive metaboliser phenotypes for sparteine/debrisoquine to apparent 'poor metabolisers).
Introduction
A common feature of substrates undergoing polymorphic oxidation by debrisoquine/sparteine oxidase (cytochrome P450 2D6; CYP2D6) is a lipophilic domain and a strongly basic nitrogen atom. Aprindine (AP), a group IC antiarrhythmic drug (Fasola & Carmichael, 1974) , has these characteristics and is metabolised extensively in humans.
Thus, three main metabolites of AP have been identified in the urine of healthy volunteers, with recovery of negligible amounts of the parent compound (Ito et al., 1986; Murphy, 1974) (Figure 1) .
After a single oral dose of 200 mg AP hydrochloride, about 65% of the administered dose is excreted in the urine within 120 h with the remaining 35% being found in faeces (Fasola & Carmichael, 1974) . Over 72% of the hydroxylated metabolites in urine were recovered as conjugates (Dodion et al., 1974; Ito et al., 1986) .
We now report that AP is a competitive inhibitor of the in vitro formation of (2S)-hydroxysparteine' ((2S)-OH-SP) (Ebner et al., 1991) , 5,6-didehydrosparteine (5,6-DDHSP) and of the 5-hydroxylation of propafenone, another substrate of CYP2D6. In The structure of aprindine and its major metabolites in man. *Relative recovery in the urine (% of administered dose, 24 h) after a single oral dose of 100 mg aprindine hydrochloride (Ito et al., 1986) .
'The carbinolamine (2S)-OH-SP is the major metabolite of SP excreted in urine. Alkaline sample extraction for GC analysis leads to the formation of the enamine 2,3-didehydrosparteine ('2-dehydrosparteine') by elimination of water. Correspondence: Dr T. Ebner, Dr Margarete Fischer-Bosch-Institut fur Klinische Pharmakologie, Auerbachstrasse 112, D-7000 Stuttgart 50, Germany Methods AP hydrochloride and desethylaprindine hydrochloride were gifts from Dr Madaus GmbH (Koin, FRG) . N,Ndimethyl-N' -2-indanyl-N'-phenyl-1 ,3-propanediamine hydrochloride was synthesised as described by Vanhoof & Clarebout (1970) . Quinidine and SP monohydrogensulphate pentahydrate were purchased from Aldrich (Steinheim, FRG) . N-O-bis(trimethylsilyl)-trifluoroacetamide (BSTFA) was purchased from Pierce (Oud Bijerland, The Netherlands). The diperchlorate of 17-ethylsparteine, 1,2-, and 1,6-didehydrosparteinium monoperchlorates were synthesised (Ebner et al., 1989; Leonard et al., 1955; Rink & Grabowski, 1956 ). (R)and (S)-propafenone were provided by Knoll AG (Ludwigshafen, FRG). Samples of kidney donor livers were generous gifts from Professor U. A. Meyer, Basel, Switzerland. Liver samples 1 and 2 were assigned to the EM phenotype on the basis of genotyping (Xba I RFLP and PCR analysis) and enzyme kinetic studies of SP and bufuralol metabolism. Liver sample 3 showed the 44/44 kb/D6-B (Broly et al., 1991) mutation which is characteristic of PMs and also exhibited impaired formation of SP metabolites, bufuralol 1-hydroxylation and propafenone 5-hydroxylation. LKM-1 autoantibody positive sera were kindly provided by Professor M. Manns, University of Mainz, FRG, and have been described and characterised elsewhere (Manns et al., 1990) .
Microsomes were prepared from three liver samples as described previously (Osikowska-Evers & Eichelbaum, 1986) . Protein was determined by the Lowry method (Lowry et al., 1951) .
Incubation and assay conditions
Microsomal protein (50 Rg) was incubated with AP in the presence of 4.8 mm NADPH and 6 mm MgCl2 in 0.1 M phosphate buffer (pH 7.4) at 370 C for 40 min. The total incubation volume was 250 R.aI. Linearity of the rate of metabolite formation with respect to concentration of microsomal protein (100-400 ,ug ml-') and incubation time (20-50 min) was observed. AP hydrochloride was dissolved in water and added to the incubation mixtures to final concentrations of 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, 200, 500 FLM. Incubations were stopped by addition of 10 ,ul perchloric acid (60% w/v) and stored frozen at -20°C. For inhibition studies, microsomes were preincubated at room temperature for 1 h with human serum (5-10 ,u) from either control or LKM-I autoantibody positive patients. Results are expressed as per cent inhibition of product formation with LKM-I autoantibody positive serum relative to control serum. Incubations with SP and propafenone enantiomers were performed as described previously (Kroemer et al., 1989; Osikowska-Evers & Eichelbaum, 1986) . AP was used at concentrations of 1, 5, 10, 20, 50 FM for inhibition of propafenone 5-hydroxylation and at 0.05, 0.1, 0.2, 0.5, 0.8, 1.0 FM for inhibition of SP metabolism. Substrate concentrations were 150, 300, 400 Fm (SP), 10, 20, 40 pM ((R)-propafenone), and 20, 40, 80 F1M ((S)-propafenone). Quinidine was used as an inhibitor of in vitro AP (5 FM) metabolism at concentrations of 1 ALM and 10 FiM.
Samples from the incubations with AP were analysed by capillary gas chromatography (GC) on a Carlo Erba Fractovap 4169 gas chromatograph with a cooled oncolumn injector and a NP-sensitive detector. A 25 m x 0.32 mm HP-1 crosslinked methyl silicone gum (film thickness 1.05 jim) capillary column (Hewlett Packard, Boblingen, F.R.G.) was connected to a deactivated capillary column (1.5 m x 0.32 mm) which served as a retention gap. Helium (2.5 ml min-) was used as the carrier gas. Mass spectra of AP metabolites were obtained with a Hewlett Packard HP 5790 MSD in the positive ion/electron impact ionisation (70 eV) mode. AP and Ndesethyl-aprindine were quantified using the synthetic reference compounds and N,N-dimethyl-N'-2-indanyl-N'-phenyl-1,3-propanediamine, the dimethyl homologue of AP, as internal standard. The sensitivity of the NP detector was found to be similar for AP, N-desethylaprindine and internal standard. Since no reference compounds for the phenolic metabolites were available, the calibration curve of N-desethylaprindine was also employed for the quantification of HA1 and HA2. Standard curves for AP and desethylaprindine were linear over a range of 0.1-5 nmol ml-l (r2= 0.995 and 0.993 for AP and desethylaprindine, respectively). The within-day coefficients of variation were 7.9% and 7.2% for assay fo desethylaprindine and 8.8% and 5.5% for assay of AP (concentrations 0.2 nmol ml-1 and 1 nmol ml-', n = 6). The lower limit of determination was 20 pmol mlfor AP and 28 pmol mlfor desethylaprindine.
Incubation mixtures, spiked with 250 pmol of internal standard, were brought to pH 9.5 by the addition of 50 RI of saturated sodium bicarbonate buffer and extracted with 40 RI dichloroethane by vigorous shaking. The organic phase was separated by centrifugation (5 min, 10 000 g). The clear organic phase (2.5 RI) was injected into the gas chromatograph at 650 C. The temperature was raised at a rate of 300 C min-1 to a final temperature of 3000 C. Average retention times were 7.2 min for N,Ndimethyl-N'-2-indanyl-N'-phenyl-1 ,3-propanediamine, 7.7 min for N-desethyl-aprindine, 8.2 min for AP, 10.4 min for HA1, and 10.8 min for HA2.
Enzyme kinetics
Vmax and Km values were determined on the basis of a one-enzyme model (Wilkinson, 1986) . Weighted data were fitted by the Michaelis-Menten equation using an interactive nonlinear least squares regression programme.
Ki was estimated from the intercepts of Dixon plots constructed by linear regression analysis of mean data from duplicate incubations.
Results

Identification of aprindine metabolites
When AP was incubated with microsomes from both EM livers, the formation of three metabolites was observed. One metabolite exhibited the same retention time (8.2 min) and mass spectrum as synthetic N-desethylaprindine. The structures of the two metabolites with longer retention times (10.4 min and 10.8 min) were elucidated on the basis of their mass spectra. The PI/El mass spectrum of the metabolite with the shorter retention time (HA1) showed a quasimolecular ion (M+, m/z = 338; m/z = 410 after derivatisation with BSTFA) and a characteristic fragment with an m/z of 149.1. Derivatisation with BSTFA resulted in a shift of this fragment to an m/z value of 221.2 indicating the formation of a trimethylsilyl ether derivative. In contrast, the metabolite with the longer retention time (HA2) did not exhibit a fragment with an m/z of 149.1, but a fragment at 133.2 was observed. A shift of this fragment to an m/z of 205.1 was found after derivatisation with BSTFA. These results are in complete accordance with the structures of HA, and HA2 reported in the literature (Dodion et al., 1974; Murphy, 1974) . However, the exact location of the OHgroups in the phenyl-and indanyl-rings of the AP molecule cannot be deduced on the basis of the mass spectra. It was assumed that HA1 is the para-hydroxylated product as the relative retention times of HA1 and HA2 compared to AP and desethylaprindine were similar to those reported using GC analysis (Kawano et al., 1989; Murphy, 1974) . Figure 2 shows Eadie-Hofstee plots for the formation of HA1 and HA2 by EM liver microsomes. Vmax, Km, and Vma,/Km values for the formation of N-desethylaprindine, HA1 and HA2 are listed in Table 1 . HA1 and HA2 were formed exclusively by EM liver microsomes following incubation with AP at concentrations < 20 FLM. At higher AP concentrations small amounts of both hydroxy metabolites were also present in samples from incubations with microsomes from the PM liver. However, the peak areas for HA1 and HA2 never exceeded 8% of the N-desethylaprindine peak and these products were observed only at AP concentrations > 20 FM. No metabolites were found in control experiments without NADPH or with heat-denaturated microsomes (15 min, 900 C).
Enzyme kinetic parameters for aprindine metabolism
Inhibition of SP and propafenone metabolism
Competitive inhibition was observed for the formation of SP metabolites and propafenone 5-hydroxylation.
Calculated Ki values were 17 nm for the formation of (2S)-OH-SP and 18 nm for the formation of the minor metabolite 5,6-DDHSP. Quinidine competitively inhibited the formation of (2S)-OH-SP with a Ki of 50 nM and the formation of 5,6-DDHSP with a Ki of 38 nm. Competitive inhibition by AP was also observed for the formation of 5-hydroxypropafenone. The apparent K; was 2.8 FLM for the (R)-enantiomer and 2.1 FM for the (S)-enantiomer. AP did not inhibit propafenone Ndesalkylation.
Inhibition of aprindine metabolism
Addition of quinidine to incubations with AP decreased the formation of HA1 and HA2 by 32% + 12%-80% + 21% (n = 3) whereas AP N-dealkylation was unaffected.
When AP (5 pRM) was incubated in the presence of 5 pI LKM-1 positive human serum per mg of microsomal protein, 86% ± 9% and 90% ± 6% (n = 2) decreases in the formation of HA1 and HA2 were observed. At 10 ,ul LKM-1 positive serum per mg of microsomal protein, no hydroxylated metabolites of AP could be detected. N-desethylaprindine formation was decreased by 35% and 52% (AP concentration 50 JIM) with 5 and 10 RI LKM-1 positive serum, respectively.
Discussion
The same primary metabolites of AP found in the urine after administration of AP were formed by microsomal in vitro oxidation. The in vitro findings indicate a high capacity for the formation of desethylaprindine and a lower capacity for the formation of the two hydroxylated metabolites as reflected in the marked differences in the Vmax/Km values for HA1 and HA2 compared with those of desethylaprindine. Therefore, at the low plasma concentrations of AP associated with therapeutic use (3 to 5 FM (1-2 pg ml-1)), (Evardsson & Olsson, 1987) , the hydroxylated compounds HA1 and HA2 should be the major metabolic products. This prediction is in accordance with the recovery of AP metabolites in urine. Thus, after a single oral dose of 100 mg AP hydrochloride only 0.26 ± 0.14% (n = 5, mean ± s.e. mean) of the dose was excreted as desethylaprindine, whereas after treatment with 3-glucuronidase, 6.6 ± 0.6% and 37.0 ± 10.7% of the dose was recovered as HA1 and HA2, respectively (Ito et al., 1986) . It has been proposed that the nonlinear pharmacokinetics of AP observed after multiple dosage (Kobari et al., 1984; Yokota et al., 1987) is caused by saturation of its metabolism. The low capacity of CYP2D6 for the formation of HA1 and HA2, representing the major metabolic pathways, is a reasonable explanation for this finding. AP was found to be a potent inhibitor of SP metabolism.
Thus, the Ki value for the formation of the two SP metabolites is less than that for quinidine (Otton et al., 1982) , a potent competitive inhibitor of CYP2D6, both in vitro and in vivo. Because of the finding of biphasic Michaelis-Menten kinetics for in vitro SP oxidation, indicating a second low affinity enzyme which is not inhibited by quinidine (Tyndale et al., 1989) , SP concentrations used in this study were c 640 FLM. AP also inhibited the CYP2D6-mediated 5-hydroxylation of propafenone. The apparent Ki values for the inhibition of propafenone hydroxylation, however, were much higher than the Ki values for SP metabolism. Because AP is an alternative substrate for CYP2D6 with a Vmax value in the same range as the substrates investigated (Vmax: propafenone 5-hydroxylation 92 pmol min-1 mg-' for the (R)and 166 pmol min-' mg-' for the (S)enantiomer (Kroemer et al., 1991) enzyme kinetic experiments may overestimate the true value of Ki. Differences in the apparent Ki values for propafenone and SP metabolism might reflect also differences in the partitioning of the substrates into microsomal membranes. Inhibition of AP hydroxylation was observed with quinidine which might reflect competition of both compounds for the same binding site. As AP hydroxylation was not completely inhibited by quinidine, another quinidine insensitive enzyme might also contribute to the formation of HA1 and HA2.
Autoantibodies against a microsomal antigen of liver and kidney microsomes (LKM-1) have been shown to interact with CYP2D6 (Zanger et al., 1988) . Thus, serum from patients suffering from LKM-1 positive chronic active hepatitis strongly inhibits the in vitro metabolism of SP and other CYP2D6 substrates such as bufuralol or propafenone (Kroemer et al., 1989) . LKM-1 positive sera which showed a marked inhibition of (2S)-OH-SP formation in a previous study (Manns et al., 1990 ) also caused almost complete blockade of HA1 and HA2 production. Surprisingly, there was also a reduction in the formation of N-desethylaprindine. This could be due to a possible involvement of CYP2D6 in AP Ndeethylation or inhibition of other cytochrome P-450 isoenzymes by LKM-1 autoantibodies.
The first of these possibilities seems unlikely since our results using microsomes from a PM liver and inhibition experiments with quinidine indicate that the oxidative N-deethylation of AP is catalysed by cytochrome P-450 isoenzyme(s) different from that which forms HA1 and HA2. Formation of the latter is mediated mainly by CYP2D6. The high affinity of AP for CYP2D6 suggests that it should inhibit in vivo metabolism of other drugs sharing the sparteine/debrisoquine polymorphism. Preliminary results of a study of one EM and one PM of SP revealed undetectable concentrations of HA1 and HA2 in the urine of the PM subject after a single oral dose of 50 mg AP hydrochloride. In contrast, HA1 and HA2 were present as the main metabolites in the urine of the EM. In addition, the EM showed a more than 10fold increase in the urinary metabolic ratio (MR) of SP when phenotyped before and 12 h after AP intake, which would have resulted in an incorrect phenotype assignment (MR is defined as the quotient of unchanged SP and the sum of (2S)-OH-SP and 5,6-DDHSP excreted in the urine). Therefore, AP treatment should result not only in impaired metabolism of other drugs by CYP2D6, but will also produce incorrect phenotype assignments (Eichelbaum & Gross, 1990) . As HA1 and HA2 are the main metabolites of AP, PMs should exhibit significant differences in AP pharmacokinetics which could have clinical implications for the treatment with this antiarrhythmic drug. The use of AP is associated with a high incidence of adverse reactions and the compound has a narrow therapeutic range. Unpredictable and severe side-effects during AP treatment have restricted the use of this drug in most countries. However, recent publications on AP pharmacokinetics and pharmacodynamics from Japan seem to reflect a more frequent use of the drug in this country where there is a much smaller percentage PMs (Horai et al., 1990; Ishizaki et al., 1987; Nakamura et al., 1985) .
